Bilous et al. reported a HER2 3+ positivity rate of 12% in a large study with 1536 breast carcinomas, and Chia et al. published a rate of 10.2% of HER2 positive breast cancers in their study cohort of 4444 invasive breast cancers [16,17]. Here, ERBB2 is linked to breast carcinoma.